Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The development of efficient mucosal vaccines is strongly dependent on the use of appropriate vectors. Various biological systems or synthetic nanoparticles have been proposed to display and deliver antigens to mucosal surfaces. The spore, a metabolically quiescent and extremely resistant cell, has also been proposed as a mucosal vaccine delivery system and shown able to conjugate the advantages of live and synthetic systems. Several antigens have been displayed on the spore by either recombinant or non-recombinant approaches, and antigen-specific immune responses have been observed in animals immunized by the oral or nasal route. Here we review the use of the bacterial spore as a mucosal vaccine vehicle focusing on the advantages and drawbacks of using the spore and of the recombinant vs. non-recombinant approach to display antigens on the spore surface. An overview of the immune responses induced by antigen-displaying spores so far tested in animals is presented and discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341597 | PMC |
| http://dx.doi.org/10.3390/ijms241310880 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing mucosal vaccination: Exploiting Lactobionic acid-modified chitosan for superior gene delivery systems.
Int J Biol Macromol
September 2025
CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal; CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, 3004-504, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, 3000-548, Portugal. Electronic a
The increasing prevalence of respiratory disorders highlights the urgent need for effective mucosal vaccines that elicit targeted immune responses at pathogen entry sites. However, the advancement of mucosal vaccines is limited by challenges in antigen delivery and overcoming mucosal immune tolerance. In this study, we developed a gene delivery platform using chitosan functionalized with lactobionic acid (LA) to enhance targeting of antigen-presenting cells and to form stable DNA polyplexes with high transfection efficiency.
View Article and Find Full Text PDFOral Immunization with Recombinant Saccharomyces cerevisiae expressing TM1 of Mycoplasma gallisepticum induces Unique Specific Antibodies and Protective Immunity.
Microb Pathog
September 2025
School of Life Science, Liaoning University, Chongshanzhong-Lu No. 66, Shenyang, 110036, China. Electronic address:
Mycoplasma gallisepticum (MG) is one of the main pathogens causing chronic respiratory diseases in chickens, which seriously affects the sustainable and healthy development of the poultry industry and leading to heavy economic losses. Therefore, we developed a safe, efficient, convenient, and low-cost MG oral vaccine. The vaccine is based on a recombinant yeast surface display system to compensate for the shortcomings of existing vaccines.
View Article and Find Full Text PDFAnti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus.
Int Immunol
September 2025
Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toll-like receptor 7 (TLR7) is an endosomal sensor that responds to both pathogen-derived and self-derived single-stranded RNA (ssRNA). Responses of TLR7 to self-derived ssRNA have been implicated in the development of autoimmune diseases, such as systemic lupus erythematosus (SLE). TLR7 antagonists and inhibitory anti-TLR7 monoclonal antibodies (mAbs) can protect lupus-prone NZBWF1 mice from lethal nephritis.
View Article and Find Full Text PDFIntestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newborns.
Clin Infect Dis
September 2025
Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth Health, Lebanon, New Hampshire, USA.
Background: Approximately 1.5 billion doses of novel oral polio vaccine type 2 (nOPV2) have been administered in response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks since 2021. Although infants are eligible to receive the vaccine from birth, the induction of intestinal mucosal immunity by nOPV2 in newborns has not been directly evaluated.
View Article and Find Full Text PDFUpdates in Clinical Management of Recurrent Urinary Tract Infections.
Obstet Gynecol
September 2025
Division of Urogynecology & Reconstructive Pelvic Surgery and the Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, North Carolina; and the University of Pittsburgh Medical Center-Magee Womens Hospital, Pittsburgh, Pennsylvania.
Urinary tract infections (UTIs) are common and burdensome in women. Here, we discuss challenges with our current models of care and how evolving insights into the female urogenital microbiome have advanced the understanding of how we diagnose, treat, and prevent recurrent UTIs in nonpregnant adult women. Traditional care models attribute recurrent UTIs mainly to gastrointestinal sources, resulting in significant emphasis on eradicating pathogens with potential overreliance on antibiotics.
View Article and Find Full Text PDF